By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said it has completed its $80 million purchase of Rules-Based Medicine.

RBM will remain based in Austin, Texas and will operate as a wholly owned subsidiary of Myriad. RBM discovers biomarkers for pharmaceutical and biotechnology firms using its multiplex immunoassay technology. It will continue its collaborations with pharma partners in companion diagnostic discovery and carry out internal research projects, Myriad said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.